Combination therapy with a long-acting amylin analogue and a glucagon-like peptide-1 (GLP-1) receptor agonist results in ...

W. Timothy Garvey, M.D., served as lead author in the clinical trial. A new combination drug therapy is showing extraordinary ...

Despite being on the market for less than three years, GLP-1 medicines, Mounjaro and Zepbound, became key top-line drivers ...

Novo Nordisk shares have come under pressure amid weight-loss drug competition, while UK health officials have launched a ...

According to a Motilal Oswal report, real estate giants will sustain growth through new launches with a 12% CAGR from FY25-27. The sector's prospects remain robust, though regulatory hold-ups and ...

Eli Lilly poised for 30-50% growth in 12 months with a strong value and growth nexus. Click here to read more on LLY stock.

Novo Nordisk is seen as having fallen behind in the race for new obesity drugs. It argues it is playing the long game.